Table 2.
Patient characteristics of the mCRPC response study.
| Pt No. | Age (year) | Metastatic Site (Number) | Drug Used | Baseline Parameters | 3-Month Parameters | Other Clinical Parameters | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PSA (ng/mL) | TBR | PSA (ng/mL) | TBR | PCWG3 (Subsequent Treatment) |
Alive/Dead | PFS (m) | OS (m) | ||||||||||
| 5 min p.i. | 30 min p.i. | 5 min p.i. | 30 min p.i. | ||||||||||||||
| Sum | Sumw | Sum | Sumw | Sum | Sumw | Sum | Sumw | ||||||||||
| 1 | 75 | left SV, right iliac bone. | Enzalutamide | 95.25 | 28.45 | 14.31 | 38.83 | 19.42 | 1.08 | 3.80 | 1.98 | 4.89 | 1.34 | SD (Docetaxel) |
Alive | 34.63 | 48.43 |
| 2 | 73 | node (1), T8 bone. | Enzalutamide | 10.54 | 19.80 | 13.98 | 17.48 | 10.81 | 2.22 | 11.37 | 5.55 | 8.76 | 1.18 | PR ∏ (Docetaxel) |
Dead | 11.93 | 29.17 |
| 3 | 58 | bone (sacrum and scapula) | Abiraterone | 9.67 | 13.42 | 7.87 | 13.56 | 7.73 | 3.02 | 6.17 | 3.74 | 8.91 | 1.73 | SD (Docetaxel) |
Alive | 47.73 | 53.80 |
| 4 | 63 | multiple bone mets (19), nodes (3) | Abiraterone | 33.44 | 170.51 | 8.65 | 191.21 | 9.52 | 14.5 | 181.36 | 9.60 | 211.00 | 0.81 | SD (Carboplatin/Etoposide) |
Dead | 9.13 | 29.53 |
| 5 | 80 | left SV, peritoneal lesions (2), C3 bone (1) | Abiraterone | 198 | 27.91 | 7.75 | 23.91 | 6.45 | 63.67 | 30.91 | 8.29 | 27.90 | 1.06 | SD (Cabazitaxel) |
Dead | 14.47 | 38.67 |
| 6 | 74 | bone mets (7), node (1) | Enzalutamide | 228.82 | 18.51 | 3.34 | 21.25 | 3.26 | 92.95 | 14.88 | 2.33 | 14.88 | 2.17 | SD (Docetaxel) |
Dead | 12.13 | 28.10 |
| 7 | 84 | right iliac bone (1). | Abiraterone | 27.19 | 2.62 | 2.62 | 4.10 | 4.10 | 8.17 | 1.38 | 1.38 | 1.69 | 1.69 | SD (‡ Nil) |
Dead | 25.60 | 25.80 |
| 8 | 74 | nodes (2) | Enzalutamide | 22.54 | 7.70 | 3.50 | 6.62 | 3.50 | 14.90 | N/A | N/A | N/A | N/A | SD (Enzalutamide) |
Alive | 36.00 | 36.00 |
| 9 | 69 | bone (2) | Enzalutamide | 94.47 | 97.32 | 8.56 | 98.73 | 8.77 | 32.78 | N/A | N/A | N/A | N/A | N/A († Treatment break) |
Alive | 34.00 | 36.00 |
SV, seminal vesicle; TBR, tumour-to-background ratio; p.i., post-injection; PSA, prostate-specific antigen; PCWG3, prostate cancer working group 3 (at 3 months); SD, stable disease; PR, partial response; N/A, not available as overseas. ∏ Had nodal disease that responded to treatment on the 3-month follow-up. Subsequently, patient showed multiple (routine PSMA-avid) bone metastases and died from their disease. ‡ Nil further due to Dementia. † Treatment break abroad (in COVID-19 lockdown). Then, progressive disease on return. Radium-223 and radiotherapy.